Premium
Motor fluctuations in Parkinson's disease: Central pathophysiological mechanisms, part II
Author(s) -
Mouradian M. M.,
Junecos J. L.,
Fabbrini G.,
Schlegel J.,
Bartko J. J.,
Chase T. N.
Publication year - 1988
Publication title -
annals of neurology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.764
H-Index - 296
eISSN - 1531-8249
pISSN - 0364-5134
DOI - 10.1002/ana.410240304
Subject(s) - levodopa , dyskinesia , parkinson's disease , dopamine , degenerative disease , psychology , medicine , central nervous system disease , anesthesia , pathophysiology , disease
The contribution of central pharmacodynamic mechanisms to the pathogenesis of motor fluctuations in advanced Parkinson's disease was studied in 29 patients by evaluating their acute response to intravenously injected. levodopa. While the threshold dose for an antiparkinsonian effect did not change, that for induction of dyskinesia showed a progressive reduction in 4 groups: (1) levodopa‐naive patients, (2) those with a stable response to oral administration, and (3) those with wearing‐off or (4) on‐off fluctuations. Concomitantly, the therapeutic window for levodopa narrowed and the levodopa dose—antiparkinsonian response slope increased. The antiparkinsonian threshold dose correlated best with duration of symptoms; the dyskinesia threshold dose, therapeutic window, and dose‐response slope related most closely with the duration of levodopa treatment. The differing dose‐response profiles for the antiparkinosonian and dyskinetic effects suggest involvement of Septemberarate pharmacological mechanisms. The present results, taken together with previous observations that the wearing‐off phenomenon responds promptly to plasma levodopa stabilization while on‐off fluctuations tend to diminish over several days, suggest that postsynaptic modifications, presumably at the receptor level, serve as the major determinant for the increasing difficulty with optimal dose adjustment and motor fluctuations, especially of the on‐off type, which complicate levodopa therapy of patients with advance Parkinson's disease.